Analysts think IBRX stock price could increase by 125%
Feb 12, 2025, 12:25 PM
-8.83%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
6 analysts think IBRX stock price will increase by 125.24%. The current median analyst target is $7.14 compared to a current stock price of $3.17. The lowest analysts target is $4.80 and the highest analyst target is $31.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
